company background image
24H logo

Hansa Biopharma DB:24H Stock Report

Last Price

€3.05

Market Cap

€229.2m

7D

24.6%

1Y

52.8%

Updated

23 Dec, 2024

Data

Company Financials +

Hansa Biopharma AB (publ)

DB:24H Stock Report

Market Cap: €229.2m

24H Stock Overview

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details

24H fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Hansa Biopharma AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hansa Biopharma
Historical stock prices
Current Share PriceSEK 3.05
52 Week HighSEK 4.80
52 Week LowSEK 2.14
Beta1.53
1 Month Change23.12%
3 Month Change-12.72%
1 Year Change52.76%
3 Year Change-65.00%
5 Year Change-59.47%
Change since IPO-85.06%

Recent News & Updates

Recent updates

Shareholder Returns

24HDE BiotechsDE Market
7D24.6%-3.5%-2.0%
1Y52.8%-14.7%6.9%

Return vs Industry: 24H exceeded the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 24H exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is 24H's price volatile compared to industry and market?
24H volatility
24H Average Weekly Movement9.1%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 24H's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 24H's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007135Søren Tulstrupwww.hansabiopharma.com

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

Hansa Biopharma AB (publ) Fundamentals Summary

How do Hansa Biopharma's earnings and revenue compare to its market cap?
24H fundamental statistics
Market cap€229.17m
Earnings (TTM)-€56.91m
Revenue (TTM)€16.46m

13.9x

P/S Ratio

-4.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
24H income statement (TTM)
RevenueSEK 189.39m
Cost of RevenueSEK 88.19m
Gross ProfitSEK 101.20m
Other ExpensesSEK 755.98m
Earnings-SEK 654.78m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)-9.66
Gross Margin53.43%
Net Profit Margin-345.73%
Debt/Equity Ratio-294.7%

How did 24H perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansa Biopharma AB (publ) is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Christian LeeABG Sundal Collier Sponsored
Madhu KumarB. Riley Securities, Inc.